Increased in situ gelatinolytic activity in renal cell tumor tissues correlates with tumor size, grade and vessel invasion

International Journal of Cancer

Volumn 106, Issue 4, 2003, Pages 480-485

  Kamiyai, Naoto ^a   Kishimoto, Takashi ^a   Suzuki, Hiroyoshi ^a   Sekita, Nobuyuki ^a   Nagai, Yuichiro ^a   Oosumi, Nobuyuki ^a   Kito, Hiroki ^a   Tochigi, Naobumi ^a   Shinbo, Masataka ^a   Nemori, Ryouichi ^b   Ichikawa, Tomohiko ^a   Igarashi, Tatsuo ^a   Ito, Haruo ^a   Ishikura, Hiroshi ^a  

^a CHIBA UNIVERSITY   (Japan)

^b NONE

Author keywords

Film in situ zymography; Gelatin zymography; Gelatinase activity; Matrix metalloproteinases; Renal cell carcinoma; RT PCR; Western blotting

Indexed keywords

COLLAGEN; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; CLINICAL FEATURE; COLLAGEN DEGRADATION; CONTROLLED STUDY; ENZYME ACTIVITY; GELATINOLYSIS; HISTOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; METASTASIS; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; WESTERN BLOTTING; ZYMOGRAPHY;

ADENOCARCINOMA; ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; GELATIN; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UP-REGULATION;

EID: 0043095378     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11272     Document Type: Article

References (52)

1. Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, O'Sullivan B, Sobin LH, Yarbro JW. Kidney. AJCC Cancer Staging Manual, 5th ed. Philadelphia: Lippincott-Raven, 1997. 231-9.
2. Guinan PD, Vogelzang NJ, Fremgen AM, Chmiel JS, Sylvester JL, Sener SF, lmperato JP. Renal cell carcinoma: tumor size, stage and survival. J Urol 1995;153:901-3.
3. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-63.
4. Bretheau D, Lechevallier E, de Fromont M, Sault MC, Rampal M, Coulange C. Prognostic value of nuclear grade of renal cell carcinoma. Cancer 1995;76:2544-9.
5. Pound CR, Partin AW, Epstein JI, Simons JW, Marshall FF. Nuclear morphometry accurately predicts recurrence in clinically localized renal cell carcinoma. Urology 1993;42:243-8.
6. Morell-Quadreny L, Clar-Blanch F, Fenollosa-Enterna B, Perez-Bacete M, Martinez-Lorente A, Llombart-Bosch A. Proliferating cell nuclear antigen (PCNA) as a prognostic factor in renal cell carcinoma. Anticancer Res 1998;18:677-82.
7. Haitel A, Wiener HG, Blaschitz U, Marberger M, Susani M. Biologic behavior of and p53 overexpression in multifocal renal cell carcinoma of clear cell type: an immunohistochemical study correlating grading, staging, and proliferation markers. Cancer 1999;85:1592-8.
8. Onda H, Yasuda M, Serizawa A, Osamura RY, Kawamura N. Clinical outcome in localized renal cell carcinomas related to immunoexpression of proliferating cell nuclear antigen, Ki-67 antigen, and tumor size. Oncol Rep 1999;6:1039-43.
9. Curran S, Murray GI. Matrix metalloproteinases in tumor invasion and metastasis. J Pathol 1999;189:300-8.
10. McCawley LJ, Matrisian LM. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 2000;6:149-56.
11. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000;10:415-33.
12. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 2000;36:1621-30.
13. Edwards DR, Beaudry PP, Laing TD, Kowal V, Leco KJ, Leco PA, Lim MS. The roles of tissue inhibitors of metalloproteinases in tissue remodeling and cell growth. Int J Obes Relat Metab Disord 1996;20:9-15.
14. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological function. Eur J Cell Biol 1997;74:111-22.
15. Shima I, Sasaguri Y, Kusukawa J, Yamana H, Fujita H, Kakegawa T, Morimatsu M. Production of matrix metalloproteinases-2 and metalloproteinases-3 related to malignant behavior of esophageal carcinoma. Cancer 1992;70:2747-53.
16. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, Forhergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998;185:256-61.
17. Sier CF, Kubben FJ, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, van Krieken JH, Lamers CB, Verspaget HW. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996;74:413-7.
18. Murray GI, Duncan ME, Arbuckle E, Melvin WT, Fothergill JE. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut 1998;43:791-7.
19. Zeng ZS, Huang Y, Cohen AM, Guillem JG. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 1996;14:3133-40.
20. Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F. Matrix metalloproteinase 2 (MMP-2) and metalloproteinase 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer 1996;56:190-6.
21. Iwata H, Kobayashi S, Iwase H, Masaoka A, Fujimoto N, Okada Y. Production of metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinoma. Jpn J Cancer Res 1996;87:602-11.
22. Talvensaari-Mattila A, Paakko P, Hoyhtya M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 1998;83:1153-62.
23. Bramhall SR, Stamp GW, Dunn J, Lemoine NR, Neoptolemos JP. Expression of collagenase (MMP2), stromelysin (MMP3), and tissue inhibitors of the metalloproteinases (TIMP1) in pancreatic and ampullary disease. Br J Cancer 1996;182:347-55.
24. Stearns M, Stearns ME. Evidence for increase activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression. Oncol Res 1996;8:69-75.
25. Montironi R, Lucarini G, Castaldini C, Galluzzi CM, Biagini G, Fabris G. Immunohistochemical evaluation of type IV collagenase (72 kDa metalloproteinase) in prostatic intraepithelial neoplasia. Anticancer Res 1996;16:2057-62.
26. Tokuraku M, Sato H, Murakami S, Okada Y, Watanabe Y, Seiki M. Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int J Cancer 1995;64:335-59.
27. Kawano N, Osawa H, Ito T, Nagashima Y, Hirahara F, Inayama Y, Nakatani Y, Kimura S, Kitayama H, Koshikawa N, Miyazaki K, Kitamura H. Expression of gelatinase A, tissue inhibitor of matrix metalloproteinases-2, Matrilysin, and trypsin (Ogen) in lung neoplasm. Hum Pathol 1997;28:613-22.
28. Fishman DA, Bafetti LM, Stack MS. Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells. Invasion Metastasis 1996;16:150-9.
29. Young TN, Rodriguez GC, Rinehart AR, Bast RC Jr, Pizzo SV, Stack MS. Characterization of gelatinase linked to extracellular matrix metalloproteinase 2. Gynecol Oncol 1996;62:89-99.
30. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 2001;7:3113-9.
31. Kugler A, Hemmerlein B, Thelen P, Kallerhoff M, Radzun HJ, Ringert RH. Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol 1998;160:1914-8.
32. Hagemann T, Gunawan B, Schulz M, Fuzesi L, Binder C. mRNA expression of matrix metalloproteinases and their inhibitors differs in subtypes of renal cell carcinomas. Eur J Cancer 2001;37:1839-46.
33. Slaton JW, Inoue K, Perrotte P, El-Naggar AK, Swanson DA, Fidler IJ, Dinney CP. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol 2001;158:735-43.
34. 34. Furuya M, Ishikura H, Nemori R, Shibata M, Fujimoti S, Yoshiki T. Clarification of the active gelatinolytic sites in human ovarian neoplasms using in situ zymography. Hum Pathol 2001;32:163-8.
35. Zheng K, Nagai Y, Kishimoto T, Yamazawa K, Tate S, Nemori R, Hirai Y, Sekiya S, Ishikura H. A quantitative evaluation of active gelatinolytic sites in uterine endometrioid adenocarcinoma using film in situ zymography: association of stronger gelatinolysis with myometrial invasion. Jpn J Cancer Res 2002;93:516-22.
36. Nakada M, Nakamura H, Ikeda E, Fujimoto N, Yamashita J, Sato H, Seiki M, Okada Y. Expression and tissue localization of membrane-types 1,2,3 matrix metalloproteinases in human astrocytic tumors. Am J Pathol 1999;154:417-28.
37. Ikeda M, Maekawa R, Tanaka H, Matsumoto M, Takeda Y, Tamura Y, Nemori R, Yoshioka T. Inhibition of gelatinolytic activity in tumor tissue by synthetic matrix metalloproteinase inhibitor: Application of film in situ zymography. Clin Cancer Res 2000;6:3290-6.
38. Lengyel E, Schmalfeldt B, Konik E, Spathe K, Harting K, Fenn A, Berger U, Fridman R, Schmitt M, Prechtel D, Kuhn W. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol 2001;82:291-8.
39. Gelb AB. Renal Cell Carcinoma Current Prognostic Factors. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80:981-6.
40. Gold PJ, Fefer A, Thompson JA. Paraneoplastic manifestations of renal cell carcinoma. Semin Urol Oncol 1996;14:216-22.
41. Ozen H, Uygur C, Sahin A, Tekgul S, Ergen A, Remzi D. Clinical significance of serum ferritin in patients with renal cell carcinoma. Urology 1995;46:494-8.
42. Eskelinen M, Lipponen P, Nordling S. Prognostic evaluation of DNA flow cytometry and histo-morphological criteria in renal cell carcinoma. Anticancer Res 1995;15:2279-83.
43. Delahunt B, Ribas JL, Nacey JN, Bethwaite PB. Nucleolar organizer regions and prognosis in renal cell carcinoma. J Pathol 1991;163:31-7.
44. Tannapfel A, Hahn HA, Katalinic A, Fietkau RJ, Kuhn R, Wittekind CW. Prognostic value of ploidy and proliferation makers in renal cell carcinoma. Cancer 1996;77:164-71.
45. de Riese WT, Crabtree WN, Allhoff EP, Werner M, Liedke S, Lenis G, Atzpodien J, Kirchner H. Prognostic significance of Ki-67 immunostaining in nonmetastatic renal cell carcinoma. J Clin Oncol 1993;11:1804-8.
46. Bot FJ, Godschalk JC, Krishnadath KK, van der Kwast TH, Bosman FF. Prognostic factors in renal cell carcinoma; immunohistochemical detection of p53 protein versus clinicopathological parameters. Int J Cancer 1994;57:634-7.
47. Imai Y, Strohmeyer TG, Fleischhacker M, Slamon DJ, Koeffler HP. p53 mutations and Mdm-2 amplification in renal cell cancers. Mod Pathol 1994;7:766-70.
48. Yoshino S, Kato M, Okada K. Prognostic significance of microvessel count in low stage renal cell carcinoma. Int J Urol 1995;2:156-60.
49. MacLennan GT, Bostwick DG. Microvessel density in renal cell carcinoma: lack of prognostic significance. Urology 1995;46:27-30.
50. Pagenstecher A, Wussler EM, Opdenakker G, Volk B, Campbell IL. Distinct expression patterns and levels of enzymatic activity of matrix metalloproteinases and their inhibitors in primary brain tumors. J Neuropathol Exp Neurol 2001;60:598-612.
51. Lechapt-Zalcman E, Coste A, d'Ortho MP, Frisdal E, Harf A, Lafuma C, Escudier E. Increased expression of matrix metalloproteinase-9 in nasal polyps. J Pathol 2001;193:233-41.
52. Iwata H, Yamamoto M, Nemori R, Mizutani M, Iwase T, Miura S, Obata Y, Hara Y, Omoto Y, Toyama T, Yamashita H, Iwase H, Kobayashi S. Localization of gelatinolytic activity can be detected in breast cancer tissues by film in situ zymography. Breast Cancer 2001;8:111-5.